For Immediate Release: June 5, 2017
513-579-9911 x 12523
Medpace Medical Director to Present at the DIA 2017 Annual Meeting:
“Aligning Objectives of Drug Development and Patient Access”
CINCINNATI, OH — (June 5, 2017) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that Richard Scheyer, MD, Vice President of Medical Affairs at Medpace, will be presenting at the upcoming DIA 2017 Annual Meeting during the following session:
Serving the Patient Who Needs Early Access to Treatments and Achieving Meaningful Outcomes
Dr. Scheyer’s presentation is titled “Aligning Objectives of Drug Development and Patient Access”. During his presentation, he will aim to guide drug developers in designing programs that address patient needs without compromising drug development. View the session in its entirety here.
About Richard Scheyer, MD
Dr. Scheyer is a pioneer in translational medicine and Phase I/IIa drug development, with special interest in early demonstration of clinical efficacy. Prior to joining Medpace, Dr. Scheyer held a number of leadership roles at biopharmaceutical firms where he was responsible for early clinical, biomarker, and pharmacogenomic strategy and execution.
Dr. Scheyer received his B.S. in Physics from Stanford University, his M.D. from The State University of New York, Upstate Medical University, and completed residency training in Neurology and fellowship training in Epilepsy and Clinical Pharmacology at Yale University before joining the Yale faculty, serving as Associate Professor of Neurology. He has served on the Foundation for the NIH Biomarkers Consortium, and on Board of Directors of the Serious Adverse Event Consortium. Dr. Scheyer is a highly-regarded author, speaker, and industry participant and has published over 60 manuscripts and abstracts, with a focus on clinical pharmacology and therapeutic activity in areas ranging from diabetes to oncology.
Medpace is a scientifically-driven, global full-service clinical research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including hematology and oncology, cardiovascular, metabolic/diabetes, infectious diseases, and neurology and psychiatry.